

FOR IMMEDIATE RELEASE

OmniComm[®] Systems Announces Major Milestone Achievement of over 4,000 Clinical Trials

OmniComm Systems solutions expand utilization of EDC globally

Fort Lauderdale, FL, March 25, 2014 - OmniComm Systems, Inc. (OTC: OMCM), a global leading provider of clinical data management solutions for clinical trials, today announced its electronic data capture (EDC) solutions have been used in more than 4,000 live or completed clinical trials in over 55 countries across more than 30 therapeutic areas. The company's EDC solutions are widely accepted and utilized by pharmaceutical; biotechnology; contract research organizations; academic research centers and medical device companies of all sizes in all clinical trial phases. OmniComm's EDC technologies are embraced by the industry by significantly streamlining clinical processes through innovation, automation and interoperability.

The announcement comes as the company released its latest version of TrialMaster[®] its flagship EDC product. This new release includes over 300 new innovative productivity and functionality enhancements, including TrialMaster unique features like auto-redaction for faster and more efficient centralized and risk based monitoring, as well as major new automation features for exporting data utilizing OmniComm's award winning Export Utility.

TrialMaster is a key part of OmniComm's technology portfolio that includes TrialOne[®], eClinical Suite[™] and Promasys[®]. TrialOne offers end-to-end solutions for unparalleled Phase I study automation; eClinical Suite provides a comprehensive, functionally-rich solution to streamline clinical trial processes; Promasys was developed to meet the unique EDC demands of Investigator Initiated Studies and academic researcher projects. With over 15 major product releases within the last five years OmniComm continues to lead the industry in progressive and innovative EDC technology.

"This significant milestone is proof of the industry's broad acceptance of OmniComm's best-of-breed approach to developing EDC solutions," said Stephen Johnson, president, OmniComm Systems. "Our approach has been to develop targeted solutions for specific needs - TrialOne for Phase I Clinic Automation, TrialMaster for traditional phase I-IV clinical trials, eClinical Suite for hybrid trials, and Promasys for investigator initiated trials. We are thankful for our 200+ customers and will continue to develop innovative solutions that meet their particular needs."

About OmniComm Systems

OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these

Bonn Germany	Monmouth Junction, NJ United States	Southampton United Kingdom	Leiden The Netherlands	Tokyo Japan
-----------------	--	-------------------------------	---------------------------	----------------

organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Trademarks

OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Contact Info

Kuno van der Post, Ph.D.
OmniComm Systems, Inc.
+1.954.473.1254
KVanderPost@omnicomm.com

Bonn Germany	Monmouth Junction, NJ United States	Southampton United Kingdom	Leiden The Netherlands	Tokyo Japan
-----------------	--	-------------------------------	---------------------------	----------------